Aligos Therapeutics Inc
$ 6.68
-12.79%
17 Apr - close price
- Market Cap 47,398,600 USD
- Current Price $ 6.68
- High / Low $ 7.40 / 6.52
- Stock P/E N/A
- Book Value 8.67
- EPS -2.45
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.69 %
- ROE -1.97 %
- 52 Week High 13.69
- 52 Week Low 4.20
About
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California.
Analyst Target Price
$65.80
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-06 | 2025-08-06 | 2025-05-05 | 2025-03-10 | 2024-11-06 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -1.91 | -3.04 | -1.53 | -2.1133 | -13.1 | -3.07 | 0.03 | -0.22 | -0.22 | -0.41 | -0.43 | -0.53 |
| Estimated EPS | -2.4873 | -0.25 | -0.24 | -3.1533 | -3.67 | -2.16 | -0.16 | -0.19 | -0.27 | -0.47 | -0.49 | -0.48 |
| Surprise | 0.5773 | -2.79 | -1.29 | 1.04 | -9.43 | -0.91 | 0.19 | -0.03 | 0.05 | 0.06 | 0.06 | -0.05 |
| Surprise Percentage | 23.2099% | -1116% | -537.5% | 32.9813% | -256.9482% | -42.1296% | 118.75% | -15.7895% | 18.5185% | 12.766% | 12.2449% | -10.4167% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -2.29 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALGS
2026-04-17 13:40:06
Aligos Therapeutics, a San Francisco-based drugmaker, was facing a cash shortage but secured a critical deal with a Chinese partner to continue development of its hepatitis B drug, pevifoscorvir sodium. The drug is currently in a midstage clinical trial, with topline data expected next year. This partnership provides a financial lifeline for the company.
2026-04-17 07:40:06
Aligos Therapeutics has announced an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. for the development and commercialization of its chronic hepatitis B virus (HBV) drug, pevifoscorvir sodium, in Greater China. This deal includes a $25 million upfront payment and potential additional milestones up to $420 million, extending Aligos’s cash runway into Q4 2026. The company also provided updates on its Phase 2 B-SUPREME study, which is investigating pevifoscorvir sodium, and noted a neutral momentum for its stock based on technical indicators.
2026-04-16 16:09:57
Aligos Therapeutics (NASDAQ:ALGS) saw its shares rise significantly after announcing a licensing agreement with Shanghai Qingsheng Biotechnology for the development and commercialization of its cancer drug candidate, ALG-055009, in China. The deal includes upfront and milestone payments, as well as royalties on future net sales.
2026-04-16 15:09:57
Aligos Therapeutics has announced an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. for its chronic hepatitis B virus (HBV) drug, pevifoscorvir sodium, in Greater China. The deal includes a $25 million upfront payment and potential milestones up to $420 million, extending Aligos's cash runway. This agreement comes as the company continues phase 2 clinical trials for the drug, showing good tolerability and progress.
2026-04-16 11:35:23
Aligos Therapeutics has announced an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. for the development and commercialization of pevifoscorvir sodium in Greater China to treat chronic hepatitis B virus infection. Aligos will receive an upfront payment of $25 million USD and is eligible for up to $420 million USD in milestones, plus tiered royalties. This partnership leverages Amoytop's strong presence in the Chinese hepatology market, aiming to accelerate the development and regulatory success of pevifoscorvir sodium in a region with over 90 million people living with HBV.
2026-04-16 11:17:23
Aligos Therapeutics (ALGS) saw its stock jump 22% following an announcement of an exclusive licensing agreement. The company partnered with Xiamen Amoytop Biotech Co., Ltd. for the development and commercialization of pevifoscorvir sodium. This agreement specifically targets the chronic hepatitis B virus infection market across Greater China.
